Logo-jcvtr

J Cardiovasc Thorac Res. 2021;13(2): 162-168. doi: 10.34172/jcvtr.2021.31
PMID: 34326971        PMCID: PMC8302901

Original Article

Two-year safety and efficacy of Indigenous Abluminus Sirolimus Eluting Stent. Does it differ amongst diabetics? – Data from en-ABLe- REGISTRY

Kamal Sharma 1 * ORCID, Sameer Dani 2, Devang Desai 3, Prathap Kumar 4, Nirav Bhalani 5, Apurva Vasavada 6, Rutvik Trivedi 7

Cited by CrossRef: 1


1- Hommels T, Hermanides R, Fabris E, Kedhi E. Exploring new insights in coronary lesion assessment and treatment in patients with diabetes mellitus: the impact of optical coherence tomography. Cardiovasc Diabetol. 2023;22(1) [Crossref]
2- Julian G, Shau W, Chou H, Setia S. Bridging Real-World Data Gaps: Connecting Dots Across 10 Asian Countries. JMIR Med Inform. 2024;12:e58548 [Crossref]
3- Maurina M, Chiarito M, Leone P, Testa L, Montorfano M, Reimers B, Esposito G, Monti F, Ferrario M, Latib A, Colombo A. Randomized clinical trial of abluminus DES+ sirolimus‐eluting stent versus everolimus‐eluting DES for percutaneous coronary intervention in patients with diabetes mellitus: An optical coherence tomography study. Cathet Cardio Intervent. 2023;102(6):1020 [Crossref]